Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI), in patients (pts) with HER2 aberration-positive solid tumors: Updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data.

Wednesday, June 19, 2024

Dr. Minal Barve

Click above link to view abstract, login required to view video presentation.

Click to view ASCO 2024 Presentation for Trial 21-25